Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi

Parasitology

Volumn 137, Issue 2, 2010, Pages 251-259

  Batista, D G J ^a   Pacheco, M G O ^a   Kumar, A ^b   Branowska, D ^b,d   Ismail, M A ^b,c   Hu, L ^b   Boykin, D W ^b   Soeiro, M N C ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b GEORGIA STATE UNIVERSITY   (United States)

^c KING FAISAL UNIVERSITY   (Saudi Arabia)

^d SIEDLCE UNIVERSITY OF NATURAL SCIENCES AND HUMANITIES   (Poland)

Author keywords

Aromatic diamidines; Chagas disease; Chemotherapy; Trypanosoma cruzi

Indexed keywords

ANTITRYPANOSOMAL AGENT; AROMATIC COMPOUND; DB 1582; DB 1627; DB 1645; DB 1646; DB 1651; DB 1670; DIAMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CELLULAR DISTRIBUTION; CHAGAS DISEASE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; FLUORESCENCE MICROSCOPY; HEART CELL CULTURE; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

AMIDINES; ANIMALS; ANTIPROTOZOAL AGENTS; CELL NUCLEUS; CHAGAS DISEASE; CYTOPLASM; DNA, KINETOPLAST; INHIBITORY CONCENTRATION 50; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; MICROTUBULES; MITOCHONDRIA; ORGANELLES; PARASITIC SENSITIVITY TESTS; SUBCELLULAR FRACTIONS; TRYPANOSOMA CRUZI;

MAMMALIA; TRYPANOSOMA CRUZI;

EID: 77949659324     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182009991223     Document Type: Article

References (44)

1. Barrett, M. P. and Gilbert, I. H. (2006). Targeting of toxic compounds to the trypanosome's interior. Advances in Parasitology 63, 125-133. doi:10.1016/ S0065-308X(06)63002-63009
2. Bray, P. G., Barrett, M. P., Ward, S. A. and de Koning, H. P. (2003). Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends in Parasitology 19, 232-239. doi:10.1016/S1471-4922(03)00069-2.
3. Carter, N. S., Berger, B. J. and Fairlamb, A. H. (1995). Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. The Journal of Biological Chemistry 270, 28153-28157.
4. Chagas, C. (1909). Nova tripanossomíase humana: Estudos sobre a morfologia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., agente etiológico de nova entidade mórbida do homem. Memórias do Instituto Oswaldo Cruz 1, 159-218.
5. Checchi, F. and Barrett, M. P. (2008). African sleeping sickness. British Medical Journal 336, 679-700.
6. Coura, J. R. and De Castro, S. L. (2002). A critical review on Chagas disease chemotherapy. Memórias do Instituto Oswaldo Cruz 97, 3-24. doi: 10.1590/S0074-02762002000100001.
7. Cunha-Neto, E., Bilate, A. M., Hyland, K. V., Fonseca, S. G., Kalil, J. and Engman, D. M. (2006). Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39, 41-54. doi: 10.1080/08916930500485002.
8. Dantas, A. P., Barbosa, H. S. and De Castro, S. L. (2003). Biological and ultrastructural effects of the anti-microtubule agent taxol against Trypanosoma cruzi. Journal of Submicroscopic Cytology and Pathology 35, 287-294.
9. de Koning, H. P. (2001). Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Molecular Pharmacology 59, 586-592.
10. De Souza, E. M., Lansiaux, A., Bailly, C., Wilson, W. D., Hu, Q., Boykin, D. W., Batista, M. M., Araú jo-Jorge, T. C. and Soeiro, M. N. (2004). Phenyl substitution of furamidine markedly potentiates its antiparasitic activity against Trypanosoma cruzi and Leishmania amazonensis. Biochemical Pharmacology 68, 593-600. doi:10.1016/ j.bcp.2004.04.019.
11. De Souza, E. M., Oliveira, G. M., Boykin, D. W., Kumar, A., Hu, Q. and Soeiro, M. N. C. (2006). Trypanocidal activity of the phenyl-substituted analogue of fumidine DB569 against Trypanosoma cruzi infection in vivo. Journal of Antimicrobial Chemotherapy 58, 610-614. doi:10.1093/jac/dkl259.
12. De Souza, E. M., Oliveira, G. M. and Soeiro, M. N. C. (2007). Electrocardiographic finding in acutely and chronically Trypanosoma cruzi-infected mice treated by a phenyl-substituted analogue of Furamidine DB569. Drug Target Insight 2, 61-69.
13. de Souza, W. (2008). An introduction to the structural organization of parasitic protozoa. Current Pharmaceutical Design 14, 822-838.
14. Dias, J. C. (2007). Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusion Chagas disease: historical aspects, present situation, and perspectives. Memórias do Instituto Oswaldo Cruz 102, 11-18. doi: 10.1590/S0074- 02762007005000092.
15. Docampo, R., Scott, D. A., Vercesi, A. E. and Moreno, S. N. (1995). Intracellular Ca2+ storage in acidocalcisomes of Trypanosoma cruzi. The Biochemical Journal 310, 1005-1012.
16. Filardi, L. S. and Brener, Z. (1987). Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas Disease. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 755-759.
17. Gascón, J., Albajar, P., Cañ as, E., Flores, M., Gómez, I., Prat. J., Herrera, R. N., Lafuente, C. A., Luciardi, H. L., Moncayo, A., Molina, L.,Muñ oz, J., Puente, S., Sanz, G., Treviñ o, B. and Sergio-Salles, X. (2007). Diagnosis, management and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Revista Española de Cardiología 60, 285-293.
18. Guerri-Guttenberg, R. A., Grana, D. R., Ambrosio, G. and Milei, J. (2008). Chagas cardiomyopathy: Europe is not spared! European Heart Journal 29, 2587-2591. doi:10.1093/eurheartj/ehn424.
19. Higuchi, M. L., Benvenuti, L. A., Martins Reis, M. and Metzger, M. (2003). Pathophysiology of the heart in Chagas' disease: current status and new developments. Cardiovascular Research 60, 96-107. doi:10.1016/S0008-6363(03) 00361-4.
20. Ismail, M. A., Arafa, R. K., Wenzler, T., Brun, R., Tanious, F. A., Wilson, W. D. and Boykin, D. W. (2008). Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1, 2-a]pyridines. Bioorganic & Medicinal Chemistry 16, 683-691. doi:10.1016/ j.bmc.2007.10.042.
21. Marin-Neto, J. A., Simõ es, M. V. and Sarabanda, A. V. (1999). Chagas' heart disease. Arquivos Brasileiros de Cardiologia 72, 247-280.
22. Marin-Neto, J. A., Rassi, A. Jr., Morillo, C. A., Avezum, A., Connolly, S. J., Sosa-Estani, S., Rosas, F. and Yusuf, S., BENEFIT Investigators (2008). Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). American Heart Journal 156, 37-43. doi:10.1016/j.ahj.2008.04.001.
23. Mathis, A. M., Holman, J. L., Sturk, L. M., Ismail, M. A., Boykin, D. W., Tidwell, R. R. and Hall, J. E. (2006). Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrobial Agents and Chemotherapy 50, 2185-2191. doi: 10.1128/ AAC.00192-06.
24. Mathis, A. M., Bridges, A. S., Ismail, M. A., Kumar, A., Francesconi, I., Anbazhagan, M., Hu, Q., Tanious, F. A., Wenzler, T., Saulter, J., Wilson, W. D., Brun, R., Boykin, D. W., Tidwell, R. R. and Hall, J. E. (2007). Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes. Antimicrobial Agents and Chemotherapy 51, 2801-2810. doi: 10.1128/AAC.00005-07.
25. Meirelles, M. N., Araujo-Jorge, T. C., Miranda, C. F., De Souza, W. and Barbosa, H. S. (1986). Interaction of Trypanosoma cruzi with heart muscle cells : ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. European Journal of Cell Biology 41, 198-206.
26. Menna-Barreto, R. F., Salomã o, K., Dantas, A. P., Santa-Rita, R. M., Soares, M. J., Barbosa, H. S. and de Castro, S. L. (2009). Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study. Micron 40, 157-168. doi:10.1016/j.micron.2008.08.003.
27. Milei, J., Guerri-Guttenberg, R. A., Grana, D. R. and Storino, R. (2009). Prognostic impact of Chagas disease in the United States. American Heart Journal 157, 22-29. doi:10.1016/j.ahj.2008.08.024.
28. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation in cytotoxicity assays. Journal of Immunological Methods 65, 55-63.
29. Pacheco, M. G., da Silva, C. F., de Souza, E. M., Batista, M. M., da Silva, P. B., Kumar, A., Stephens, C. E., Boykin, D. W. and Soeiro, M. N. C. (2009). Trypanosoma cruzi: activity of heterocyclic cationic molecules in vitro. Experimental Parasitology 123, 73-80. doi:10.1016/j.exppara.2009.06.004.
30. Rocha, M. O., Teixeira, M. M. and Ribeiro, A. L. (2007). An update on the management of Chagas cardiomiopathy. Expert Review of Anti-Infective Therapy 5, 727-743. doi:10.1586/14787210.5.4.727
31. Rodrigues, J. C. and de Souza, W. (2008). Ultrastructural alterations in organelles of parasitic protozoa induced by different classes of metabolic inhibitors. Current Pharmaceutical Design 14, 925-938.
32. Rodriguez-Morales, A. J., Benitez, J. A., Tellez, I. and Franco-Paredes, C. (2008). Chagas disease screening among Latin American immigrants in non-endemic settings. Travel Medicine and Infectious Disease 6, 162-163.
33. Santa-Rita, R. M., Barbosa, H. S. and de Castro, S. L. (2006). Ultrastructural analysis of edelfosine-treated trypomastigotes and amastigotes of Trypanosoma cruzi. Parasitology Research 100, 187-200. doi: 10.1007/ s00436-006-0250-258
34. Silva, C. F., Batista, M. M., Mota, R. A., de Souza, E. M., Stephens, C. E., Som, P., Boykin, D. W. and Soeiro, M. N. (2007a). Activity of 'reversed' diamidines against Trypanosoma cruzi in vitro. Biochemical Pharmacology 73, 1939-1946. doi:10.1016/ j.bcp.2007.03.020.
35. Silva, C. F., Meuser, M. B., De Souza, E. M., Meirelles, M. N., Stephens, C. E., Som, P., Boykin, D. W. and Soeiro, M. N. (2007b). Cellular effects of reversed amidines on Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 51, 3803-3809. doi: 10.1128/ AAC.00047-07.
36. Silva, C. F., Batista, M. M., Batista, D. G., de Souza, E. M., da Silva, P. B., de Oliveira, G. M., Meuser, A. S., Shareef, A. R., Boykin, D. W. and Soeiro, M. N. (2008). In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi. Antimicrobial Agents and Chemotherapy 52, 3307-3314. doi:10.1128/AAC. 00038-08.
37. Soeiro, M. N. C. and De Castro, S. L. (2009). Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opinion on Therapeutic Targets 13, 105-121. doi:10.1517/14728220802623881.
38. Soeiro, M. N. C., De Castro, S. L., De Souza, E. M., Batista, D. G. J., Silva, C. F. and Boykin, D. W. (2008). Diamidine activity against trypanosomes: the state of the art. Current Molecular Pharmacology 1, 151-161.
39. Soeiro, M. N. C., De Souza, E. M., Stephens, C. E. and Boykin, D. W. (2005). Aromatic diamidines as antiparasitic agents. Expert Opinion on Investigational Drugs 14, 957-972. doi:10.1517/13543784.14.8.957.
40. Souto-Padron, T., Cunha e Silva, N. L. and de Souza, W. (1993). Acetylated alpha-tubulin in Trypanosoma cruzi: immunocytochemical localization. Memórias do Instituto Oswaldo Cruz 88, 517-528.
41. Teixeira, A. R., Nitz, N., Guimaro, M. C., Gomes, C. and Santos-Buch, C. A. (2006). Chagas disease. Journal of Postgraduate Medicine 82, 788-798.
42. Vercesi, A. E., Moreno, S. N. and Docampo, R. (1994). Ca2+/H+ exchange in acidic vacuoles of Trypanosoma brucei. The Biochemical Journal 304, 227-233.
43. Werbovetz, K. (2006). Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Current Opinion in Investigational Drugs 7, 147-157.
44. Wilson, W. D., Tanious, F. A. and Mathis, A. (2008). Antiparasitic compounds that target DNA. Biochimie 90, 999-1014. doi:10.1016/j.biochi.2008.02. 017.